West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$318.02 USD
+0.10 (0.03%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$318.02 USD
+0.10 (0.03%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Zacks News
BDX or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. WST: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
HSIC or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
MMSI vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
MMSI vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
West Pharmaceutical Services (WST) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 27.34% and 8.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.
Why West Pharmaceutical (WST) Might Surprise This Earnings Season
by Zacks Equity Research
West Pharmaceutical (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the bottom lines.
Earnings Preview: West Pharmaceutical Services (WST) Q4 Earnings Expected to Decline
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BDX vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. WST: Which Stock Is the Better Value Option?
McKesson (MCK) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 8.83% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
West Pharmaceutical Services (WST) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of -4.25% and 5.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.
McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.
West Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
West Pharmaceutical's (WST) Latest Investment to Boost Business
by Zacks Equity Research
West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.
West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?